1Lamp L J,Bianch J N,Zuccato C,et al.Effects on erythroid differentiation of plotinum compiexes of synthetic bile acid derivatives[J].Bioorganic Med Chem,2006,14(15):5204-5210.
3Liu Q H,Taninoto K J,Bungert J,et al.The Aγ-globin 3′element provides no unique functions for hunmanβ-globin locus gene regulation[J].Proc Natl Acad Sci USA,1998,95(125):9944-9949.
4Kooren J,Palstra R J,Klous P,et al.Beta-globin active chromatin Hub formation in differentiating erythroid cells and in p45 NF-E2 knock-out mice[J].J Biol Chem,2007,282(22):16544-16552.
5Vakoc C R,Letting D L,Gheldof N,et al.Proximity among distant regulatory elements at the β-globin locus requires GATA-1 and FOG-1[J].Mol Cell,2005,17(3):453-462.
6Hong W,Nakazawa M,Chen Y Y,et al.FOG-1 recruits the NuRD repressor complex to mediate transcriptional repression by GATA-1[J].EMBO J,2005,24(13):2367-2378.
7Harju-Baker S,Costa F C,Fedosyuk H,et al.Silencing of Agamma-globin gene expression during adult definitive erythropoiesis mediated by GATA-1-FOG-1-Mi2 complex binding at the-566 GATA site[J].Mol Cell Biol,2008,28(10):3101-3113.
8Uda M,Galanello R,Sanna S,et al.Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia[J].Proc Natl Acad Sci U S A,2008,105(5):1620-1625.
9Lettre G,Sankaran V G,Bezerra M A,et al.DNA polymorphisms at the BCL11A,HBS1L-MYB,and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease[J].Proc Natl Acad Sci U S A,2008,105(33):11869-11874.
10Sankaran V G,Menne T F,Xu J,et al.Human fetal hemoglobin expression is regu-lated by the developmental stage-specific repressor BCL11A[J].Science,2008,322(5909):1839-18342.
二级参考文献24
1Schrier SL, Angelucci E. New strategies in the treatment of the thalassemias. Annu Rev Med, 2005, 56:157-171.
3Anderson LJ, Wonke B, Prescott E, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in betathalassaemia. Lancet, 2002,360(9332):516-520.
4Cohen AR, Galanello R, Pennell DJ, et al. Thalassemia.Hematology, 2004:14-34.
5Wonke B. Clinical management of beta-thalassemia major. Semin Hematol, 2001,38 (4) : 350-359.
6Piga A, Gaglioti C, Fogliacco E, et al. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.Haematologica, 2003, 88(5) :489-496.
7Shalev O, Hileti D, Nortey P, et al. Transport of 14Cdeferiprone in normal, thalassaemic and sickle red blood cells. Br J Haematol, 1999, 105(4):1081-1083.
8Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.Blood, 2003,102(5) : 1583-1587.
9Wu KH, Chang JS, Tsai CH,et al.Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. Ann Hematol, 2004, 83(7) :471-473.
10Tsironi M, Deftereos S, Andriopoulos P, et al. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. Eur J Haematol, 2005, 74(1):84-85.
